Physician profile
Danielle Gibbons
NPI 1194737593
$28,867.59
in general payments reported to CMS, 2019-2025
34 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.96 · 2022: $2,542 · 2023: $3,107 · 2024: $7,690 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $11K · Travel and Lodging: $360 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,381.00 |
| Food and Beverage | $11,383.29 |
| Travel and Lodging | $360.04 |
| Education | $103.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16,973.63 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,921.46 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,851.89 | 2022-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $1,503.19 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $972.39 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $738.64 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $722.56 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $540.55 | 2022-2025 | Rexulti, Vyepti |
| Corium, LLC | $502.35 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $491.00 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $445.89 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $386.91 | 2022-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $211.69 | 2021-2025 | Qelbree |
| Boston Scientific Corporation | $183.54 | 2022-2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $174.92 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $153.13 | 2022-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $131.82 | 2022-2023 | Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $113.59 | 2024 | Ultomiris |
| Noven Therapeutics, LLC | $85.48 | 2024 | Secuado, Xelstrym |
| Genzyme Corporation | $84.50 | 2024 | |
| Abbott Laboratories | $73.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $69.19 | 2025 | |
| Collegium Pharmaceutical, INC. | $64.02 | 2025 | Jornay Pm |
| Novo Nordisk INC | $62.20 | 2021-2022 | |
| Inari Medical, INC. | $47.33 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Indivior INC. | $38.59 | 2025 | Sublocade |
| Amgen INC. | $37.40 | 2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.28 | 2022 | |
| Vanda Pharmaceuticals INC. | $35.10 | 2025 | Fanapt |
| Corcept Therapeutics | $30.52 | 2024 | Korlym |
| Validus Pharmaceuticals LLC | $26.63 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $21.50 | 2025 | Zilretta |
| Idorsia Pharmaceuticals US INC | $16.21 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Gibbons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.